NeoImmuneTech Accelerates NT-I7 Development by Strengthening SAB

NeoImmuneTech announced on the 26th that it has recruited Professors Jun Chen (Benny Chen) from Duke University School of Medicine and Suhyung Park from the Graduate School of Medical Science and Engineering at KAIST to its Scientific Advisory Board (SAB) to accelerate the development of 'NT-I7' as a treatment for Acute Radiation Syndrome (ARS) and as an immuno-oncology drug.

With this, the existing NeoImmuneTech SAB members?Dr. Rafi Ahmed, Dr. Keith Watson, Dr. Richard Kim, Dr. Hyunseok Kang, and Dr. Youngkwang Chae?will be joined by two new members, bringing the total to seven members on the SAB.

Professor Chen of Duke University School of Medicine is also a member of the Duke Cancer Institute, Duke Regeneration Center, and Duke Fitzpatrick Institute for Photonics. He collaborated with NeoImmuneTech on one preclinical study serving as a bridge for the ARS treatment development contract between NeoImmuneTech and the U.S. National Institute of Allergy and Infectious Diseases (NIAID), and is currently conducting another related study. With his addition to the SAB, he is expected to provide advisory support to facilitate the smooth progress of NeoImmuneTech's ARS development.

Professor Park from the Graduate School of Medical Science and Engineering at KAIST also serves as the director of the KAIST Center for Epidemic Preparedness. He recently published research findings elucidating the immunopathological mechanisms of various memory T cell subsets and the immuno-oncological mechanisms of tumor-infiltrating T cells and regulatory T cells in prestigious journals such as Nature Immunology and Clinical Cancer Research (CCR). Professor Park plans to provide expert advice on NeoImmuneTech’s T cell amplification effects and the development of new immuno-oncology strategies, strengthening the scientific basis for the action of NT-I7.

Sehwan Yang, CEO of NeoImmuneTech, said, “We are very pleased that Professors Chen and Park have joined NeoImmuneTech’s SAB. Especially through this SAB reinforcement, we expect to conduct consultations with U.S. government agencies more quickly and efficiently during the ARS treatment development process, thereby accelerating commercialization.”